Rinucumab
Rinucumab (REGN 2176), a monoclonal antibody, is a PDGF inhibitor. Rinucumab (REGN 2176) could be used for the study of neovascular age-related macular degeneration[1].
Product Specifications
CAS Number
[1569263-06-4]
Product Name Alternative
REGN 2176
UNSPSC
12352203
Target
PDGFR
Type
Inhibitory Antibodies
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/rinucumab.html
Purity
99.94
Solubility
10 mM in DMSO
Smiles
[Rinucumab]
Molecular Weight
(145.5 kDa)
References & Citations
[1]Megan Cully, et al. Deal watch: Novartis eyes vision-enhancing therapy for macular degeneration. Nat Rev Drug Discov. 2014 Jul;13 (7) :487.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
RPC22805-01 20 µg
Recombinant Spinacia oleracea Plastocyanin, chloroplastic (PETE), partial
Ask
View Details 
RPC22805-02 100 µg
Recombinant Spinacia oleracea Plastocyanin, chloroplastic (PETE), partial
Ask
View Details RPC22805-03 1 mg
Recombinant Spinacia oleracea Plastocyanin, chloroplastic (PETE), partial
Ask
View Details